I
ImmunityBio
A commercial-stage immunotherapy company developing novel treatments for cancer and infectious diseases.
About
ImmunityBio is a biotechnology company developing immunotherapies to treat cancer and infectious diseases by activating the patient's innate and adaptive immune systems. Their approach aims to deliver durable responses by stimulating various immune cells and building immunological memory. The company's investigational products, including ANKTIVA®, are designed to reprogram the immune system to conquer difficult diseases.
Tags
Total Employees
620
Current headcount
Company Timeline
Funding rounds, employee growth, revenue, and exits over the same period. News mentions shown as markers.
No timeline data for this period
Score Breakdown
43Traction
60Team
30Visibility
22Profile
50Community
15Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does ImmunityBio do?
ImmunityBio is a biotechnology company developing immunotherapies to treat cancer and infectious diseases by activating the patient's innate and adaptive immune systems. Their approach aims to deliver durable responses by stimulating various immune cells and building immunological memory. The company's investigational products, including ANKTIVA®, are designed to reprogram the immune system to conquer difficult diseases.
How much funding has ImmunityBio raised?
ImmunityBio has raised a total of $375M in funding. The most recent round on record is Strategic.
Where is ImmunityBio headquartered?
ImmunityBio is headquartered in Culver City, California, USA.
When was ImmunityBio founded?
ImmunityBio was founded in 2014.
What industry does ImmunityBio operate in?
ImmunityBio operates in Biotechnology, Pharmaceuticals, Healthcare, Immunotherapy, Biotech, HealthTech.
How many employees does ImmunityBio have?
ImmunityBio has approximately 620 people on record.
What is ImmunityBio's current status?
ImmunityBio's current operating status is: Acquired.